## Else-Marie LÃ, berg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4427614/publications.pdf

Version: 2024-02-01

394421 454955 1,054 61 19 30 citations g-index h-index papers 66 66 66 1601 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable?. BMC Psychiatry, 2012, 12, 221.	2.6	183
2	Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: A 1H MRS study. Schizophrenia Research, 2015, 161, 252-260.	2.0	55
3	The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry, 2016, 16, 60.	2.6	54
4	Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample ( $N = 1119$ ). Schizophrenia Research, 2016, 170, 217-221.	2.0	47
5	Neurobiology of Cognitive Remediation Therapy for Schizophrenia: A Systematic Review. Frontiers in Psychiatry, 2014, 5, 103.	2.6	44
6	Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt) Tj ETQq0 0 0	rgBT <sub>/</sub> /Ove	rlogk 10 Tf 50
7	Dynamic Functional Connectivity Patterns in Schizophrenia and the Relationship With Hallucinations. Frontiers in Psychiatry, 2020, $11$ , $227$ .	2.6	36
8	A Critical Review of Pro-Cognitive Drug Targets in Psychosis: Convergence on Myelination and Inflammation. Frontiers in Psychiatry, 2014, 5, 11.	2.6	35
9	Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study. NPJ Schizophrenia, 2021, 7, 39.	3.6	35
10	The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. Frontiers in Psychiatry, 2014, 5, 159.	2.6	30
11	Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). PLoS Medicine, 2021, 18, e1003653.	8.4	29
12	Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC Infectious Diseases, 2019, 19, 943.	2.9	28
13	Brain Age Prediction Reveals Aberrant Brain White Matter in Schizophrenia and Bipolar Disorder: A Multisample Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1095-1103.	1.5	28
14	Functional brain asymmetry and attentional modulation in young and stabilised schizophrenic patients: a dichotic listening study. Psychiatry Research, 2002, 109, 281-287.	3.3	27
15	Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. Substance Abuse Treatment, Prevention, and Policy, 2020, 15, 68.	2.2	26
16	Patient satisfaction after acute admission for psychosis. Nordic Journal of Psychiatry, 2016, 70, 321-328.	1.3	23
17	Intra-Regional Glu-GABA vs Inter-Regional Glu-Glu Imbalance: A 1H-MRS Study of the Neurochemistry of Auditory Verbal Hallucinations in Schizophrenia. Schizophrenia Bulletin, 2020, 46, 633-642.	4.3	23
18	An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use. Frontiers in Psychiatry, 2012, 3, 94.	2.6	20

#	Article	IF	CITATIONS
19	Childhood trauma in schizophrenia spectrum disorders as compared to substance abuse disorders. Psychiatry Research, 2018, 261, 481-487.	3.3	20
20	Prevalence of auditory hallucinations in Norwegian adolescents: Results from a populationâ€based study. Scandinavian Journal of Psychology, 2015, 56, 391-396.	1.5	19
21	The Beliefs about Voices Questionnaire – Revised: A factor structure from 450 participants. Psychiatry Research, 2018, 259, 95-103.	3.3	19
22	The Course of Neurocognitive Changes in Acute Psychosis: Relation to Symptomatic Improvement. PLoS ONE, 2016, 11, e0167390.	2.5	18
23	Substance use and symptoms of mental health disorders: a prospective cohort of patients with severe substance use disorders in Norway. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 20.	2.2	17
24	Auditory verbal hallucinations reflect stable auditory attention deficits: a prospective study. Cognitive Neuropsychiatry, 2015, 20, 81-94.	1.3	16
25	Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis. Acta Neuropsychiatrica, 2019, 31, 36-45.	2.1	15
26	Integrated care of severe infectious diseases to people with substance use disorders; a systematic review. BMC Infectious Diseases, 2019, 19, 306.	2.9	14
27	Cognitive Profile in Ultra High Risk for Psychosis and Schizophrenia: A Comparison Using Coordinated Norms. Frontiers in Psychiatry, 2019, 10, 695.	2.6	13
28	Psychosocial characteristics differentiate non-distressing and distressing voices in 10,346 adolescents. European Child and Adolescent Psychiatry, 2019, 28, 1353-1363.	4.7	12
29	Influence of different second generation antipsychotics on the QTc interval: A pragmatic study. World Journal of Psychiatry, 2016, 6, 442.	2.7	11
30	The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. Psychiatry Research, 2017, 250, 92-98.	3.3	10
31	Cognitive changes in patients with acute phase psychosis—Effects of illicit drug use. Psychiatry Research, 2014, 220, 818-824.	3.3	9
32	Hallucinating schizophrenia patients have longer left arcuate fasciculus fiber tracks: a DTI tractography study. Psychiatry Research - Neuroimaging, 2020, 302, 111088.	1.8	9
33	Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020. Substance Abuse Treatment, Prevention, and Policy, 2020, 15, 93.	2.2	8
34	QTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics. Schizophrenia Research and Treatment, 2013, 2013, 1-7.	1.5	7
35	Glutamate- and GABA-Modulated Connectivity in Auditory Hallucinations—A Combined Resting State fMRI and MR Spectroscopy Study. Frontiers in Psychiatry, 2021, 12, 643564.	2.6	7
36	â€~Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study. Journal of Substance Abuse Treatment, 2021, , 108667.	2.8	7

#	Article	IF	Citations
37	Neural Activation in the Ventromedial Prefrontal Cortex Precedes Conscious Experience of Being in or out of a Transient Hallucinatory State. Schizophrenia Bulletin, 2023, 49, S58-S67.	4.3	7
38	The influence of substance use on the effectiveness of antipsychotic medication: a prospective, pragmatic study. Nordic Journal of Psychiatry, 2019, 73, 281-287.	1.3	6
39	"Needing different things from different people―– a qualitative exploration of recovery in first episode psychosis. Social Work in Mental Health, 2020, 18, 75-95.	1.0	6
40	White Matter Microstructural Differences between Hallucinating and Non-Hallucinating Schizophrenia Spectrum Patients. Diagnostics, 2021, 11, 139.	2.6	6
41	The association between cytokines and psychomotor speed in a spectrum of psychotic disorders: A longitudinal study. Brain, Behavior, & Immunity - Health, 2021, 18, 100392.	2.5	6
42	Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway. BMC Psychiatry, 2022, 22, 181.	2.6	4
43	Predictors of treatment satisfaction in antipsychotic-na $\tilde{A}$ ve and previously medicated patients with acute-phase psychosis. Nordic Journal of Psychiatry, 2019, 73, 349-356.	1.3	3
44	Different response patterns in hallucinations and delusions to antipsychotic treatment. Nordic Journal of Psychiatry, 2020, 74, 497-504.	1.3	3
45	Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 39.	2.2	3
46	Changes in substance use during outpatient treatment for substance use disorders: a prospective Norwegian cohort study from 2016 to 2020. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 67.	2.2	3
47	Association between C-reactive protein levels and antipsychotic treatment during 12Âmonths follow-up period after acute psychosis. Schizophrenia Research, 2022, 241, 174-183.	2.0	3
48	Negative valence of hallucinatory voices as predictor of cortical glutamatergic metabolite levels in schizophrenia patients. Brain and Behavior, 2022, 12, e32446.	2.2	3
49	M47. AKATHISIA AND ATYPICAL ANTIPSYCHOTICS: EXPLORING ASSOCIATIONS TO SUICIDALITY AND AGITATION. Schizophrenia Bulletin, 2020, 46, S151-S152.	4.3	2
50	Cognitive change and antipsychotic medications: Results from a pragmatic rater-blind RCT. Schizophrenia Research: Cognition, 2021, 26, 100204.	1.3	2
51	Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. Acta Neuropsychiatrica, 2022, 34, 282-288.	2.1	2
52	Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations. Journal of Addictive Diseases, 2023, 41, 53-63.	1.3	2
53	T134. THE ROLE OF THE DEFAULT MODE NETWORK IN SCHIZOPHRENIA AND AUDITORY VERBAL HALLUCINATIONS – AN INVESTIGATION OF DYNAMIC FMRI RESTING STATE CONNECTIVITY. Schizophrenia Bulletin, 2020, 46, S281-S282.	4.3	1
54	S57. TREATMENT SATISFACTION IN ACUTE PHASE PSYCHOSIS: COMPARISON BETWEEN ANTIPSYCHOTIC NAÃVE AND PREVIOUSLY MEDICATED PATIENTS. Schizophrenia Bulletin, 2018, 44, S346-S346.	4.3	0

#	Article	IF	CITATIONS
55	S87. THE INITIAL CHANGE IN THE SERUM LEVEL OF C-REACTIVE PROTEIN IN ACUTE PSYCHOSIS IS ASSOCIATED WITH COGNITIVE PERFORMANCE IN LATER PHASES. Schizophrenia Bulletin, 2018, 44, S358-S359.	4.3	0
56	S3. CHILDHOOD TRAUMA AND COGNITIVE FUNCTIONING IN SCHIZOPHRENIA SPECTRUM DISORDERS: EFFECT OF FREQUENCY AND TYPE OF CHILDHOOD TRAUMA. Schizophrenia Bulletin, 2018, 44, S324-S325.	4.3	0
57	S2. CHILDHOOD TRAUMA SUBTYPES IN RELATION TO COGNITIVE FUNCTIONING IN SCHIZOPHRENIA SPECTRUM DISORDERS. Schizophrenia Bulletin, 2019, 45, S306-S306.	4.3	0
58	Peer involvement and cross-sector efforts in establishing integrated treatment of hepatitis C virus infection for people with substance use disorders: experiences from Norway. Substance Abuse Treatment, Prevention, and Policy, 2019, 14, 58.	2.2	0
59	T206. ANTIPSYCHOTIC EFFECTIVENESS FOCUSING ON INSIGHT. Schizophrenia Bulletin, 2020, 46, S310-S311.	4.3	0
60	M146. NEUROCHEMICAL MODULATION OF AUDITORY CORTEX FUNCTIONAL CONNECTIVITY IN PATIENTS WITH AUDITORY VERBAL HALLUCINATIONS. Schizophrenia Bulletin, 2020, 46, S191-S191.	4.3	0
61	The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis. Substance Use and Misuse, 2021, 56, 1880-1891.	1.4	0